Literature DB >> 14652751

Microsatellite instability analysis and/or immunostaining for the diagnosis of hereditary nonpolyposis colorectal cancer?

Britta Halvarsson1, Annika Lindblom, Eva Rambech, Kristina Lagerstedt, Mef Nilbert.   

Abstract

Hereditary nonpolyposis colorectal cancer (HNPCC) represents 2-4% of colorectal cancers and is caused by a constitutional defect in a mismatch repair (MMR) gene, most commonly affecting the genes MLH1, MSH2, and MSH6. The MMR defect results in an increased cancer risk with the greatest lifetime risks for colorectal cancer and endometrial cancer. The HNPCC-associated tumor phenotype is generally characterized by microsatellite instability (MSI) and immunohistochemical loss of expression of the affected MMR protein. We have evaluated the information obtained from MSI analysis and immunostaining for MLH1, MSH2, and MSH6 in a series of 128 tumors from patients suspected of having HNPCC. A MSI-high pattern was present in 59 of 128 (46%) tumors. Loss of immunohistochemical expression for at least one of these MMR proteins was found in 54 of 59 (92%) evaluable MSI tumors. This loss affected MLH1 in 28, MSH2 in 22, and MSH6 in 21 tumors (with MSH6 as the only loss in 4 tumors). Five (8%) MSI-high tumors showed normal MMR protein expression. All 69 microsatellite stable or MSI-low tumors showed normal immunostaining for all three proteins. In 28 patients, all with MSI-H tumors, germ-line mutations of MLH1, MSH2, or MSH6 had been identified, and a corresponding immunohistochemical loss of MMR protein expression was identified in all these cases. In summary, immunostaining for the MMR proteins MLH1, MSH2, and MSH6 had a sensitivity of 92% and a specificity of 100% for detecting MMR-deficient tumors. MMR protein immunostaining facilitates mutation analysis in suspected HNPCC patients, since it pinpoints the mutated gene, but until the genetic background to the MSI tumors with retained MMR protein expression has been clarified, we suggest that MSI and MMR protein immunostaining should optimally be combined in clinical HNPCC analysis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14652751     DOI: 10.1007/s00428-003-0922-z

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  23 in total

1.  Microsatellite instability and the clinicopathological features of sporadic colorectal cancer.

Authors:  R Ward; A Meagher; I Tomlinson; T O'Connor; M Norrie; R Wu; N Hawkins
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

2.  Characterization of hereditary nonpolyposis colorectal cancer families from a population-based series of cases.

Authors:  D J Peel; A Ziogas; E A Fox; M Gildea; B Laham; E Clements; R D Kolodner; H Anton-Culver
Journal:  J Natl Cancer Inst       Date:  2000-09-20       Impact factor: 13.506

3.  Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis.

Authors:  J Young; L A Simms; K G Biden; C Wynter; V Whitehall; R Karamatic; J George; J Goldblatt; I Walpole; S A Robin; M M Borten; R Stitz; J Searle; D McKeone; L Fraser; D R Purdie; K Podger; R Price; R Buttenshaw; M D Walsh; M Barker; B A Leggett; J R Jass
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

4.  Antibody-based screening for hereditary nonpolyposis colorectal carcinoma compared with microsatellite analysis and sequencing.

Authors:  Mariann Christensen; Niels Katballe; Friedrik Wikman; Hanne Primdahl; Flemming B Sørensen; Søren Laurberg; Torben F Ørntoft
Journal:  Cancer       Date:  2002-12-01       Impact factor: 6.860

5.  Germline, somatic and epigenetic events underlying mismatch repair deficiency in colorectal and HNPCC-related cancers.

Authors:  Siu Tsan Yuen; Tsun Leung Chan; Judy W C Ho; Annie S Y Chan; Lap Ping Chung; Polly W Y Lam; Chun Wah Tse; Andrew H Wyllie; Suet Yi Leung
Journal:  Oncogene       Date:  2002-10-24       Impact factor: 9.867

6.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC.

Authors:  H F Vasen; P Watson; J P Mecklin; H T Lynch
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

Review 7.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Authors:  C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

8.  The reliability of immunohistochemistry as a prescreening method for the diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC)--results of an international collaborative study.

Authors:  W Müller; L J Burgart; R Krause-Paulus; S N Thibodeau; M Almeida; T B Edmonston; C R Boland; C Sutter; J R Jass; A Lindblom; J Lubinski; K MacDermot; D S Sanders; H Morreau; A Müller; C Oliani; T Orntoft; M Ponz De Leon; C Rosty; M Rodriguez-Bigas; J Rüschoff; A Ruszkiewicz; J Sabourin; R Salovaara; G Möslein
Journal:  Fam Cancer       Date:  2001       Impact factor: 2.375

9.  Correlation of mismatch repair genes immunohistochemistry and microsatellite instability status in HNPCC-associated tumours.

Authors:  Andrew Ruszkiewicz; Graeme Bennett; James Moore; Jim Manavis; Barney Rudzki; Linda Shen; Graeme Suthers
Journal:  Pathology       Date:  2002-12       Impact factor: 5.306

10.  Microsatellite instability and intratumoural heterogeneity in 100 right-sided sporadic colon carcinomas.

Authors:  C Chapusot; L Martin; A M Bouvier; C Bonithon-Kopp; A Ecarnot-Laubriet; D Rageot; T Ponnelle; P Laurent Puig; J Faivre; F Piard
Journal:  Br J Cancer       Date:  2002-08-12       Impact factor: 7.640

View more
  17 in total

Review 1.  The utility of immunohistochemical detection of DNA mismatch repair gene proteins.

Authors:  Jinru Shia; Nathan A Ellis; David S Klimstra
Journal:  Virchows Arch       Date:  2004-09-29       Impact factor: 4.064

2.  EPCAM germ line deletions as causes of Lynch syndrome in Spanish patients.

Authors:  Carla Guarinos; Adela Castillejo; Víctor-Manuel Barberá; Lucía Pérez-Carbonell; Ana-Beatriz Sánchez-Heras; Angel Segura; Carmen Guillén-Ponce; Ana Martínez-Cantó; María-Isabel Castillejo; Cecilia-Magdalena Egoavil; Rodrigo Jover; Artemio Payá; Cristina Alenda; José-Luís Soto
Journal:  J Mol Diagn       Date:  2010-09-23       Impact factor: 5.568

3.  Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) - update 2012.

Authors:  Nils Rahner; Verena Steinke; Brigitte Schlegelberger; Francois Eisinger; Pierre Hutter; Sylviane Olschwang
Journal:  Eur J Hum Genet       Date:  2012-08-15       Impact factor: 4.246

4.  The added value of PMS2 immunostaining in the diagnosis of hereditary nonpolyposis colorectal cancer.

Authors:  Britta Halvarsson; Annika Lindblom; Eva Rambech; Kristina Lagerstedt; Mef Nilbert
Journal:  Fam Cancer       Date:  2006-07-12       Impact factor: 2.375

Review 5.  Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome.

Authors:  Linnea M Baudhuin; Lawrence J Burgart; Olga Leontovich; Stephen N Thibodeau
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

6.  SISE matters: the sum of information on seventy-yr-old equivalents measures pedigree information content when assessing the risk of HNPCC in a family.

Authors:  R C Green; J R McLaughlin; H B Younghusband
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

7.  Testing women with endometrial cancer to detect Lynch syndrome.

Authors:  Janice S Kwon; Jenna L Scott; C Blake Gilks; Molly S Daniels; Charlotte C Sun; Karen H Lu
Journal:  J Clin Oncol       Date:  2011-05-02       Impact factor: 44.544

8.  Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.

Authors:  M B Loughrey; P M Waring; A Tan; M Trivett; S Kovalenko; V Beshay; M-A Young; G McArthur; A Boussioutas; A Dobrovic
Journal:  Fam Cancer       Date:  2007-04-24       Impact factor: 2.375

9.  Clinical and histomolecular endometrial tumor characterization of patients at-risk for Lynch syndrome in South of Brazil.

Authors:  Silvia Liliana Cossio; Patricia Koehler-Santos; Suzana Arenhart Pessini; Heleuza Mónego; Maria Isabel Edelweiss; Luise Meurer; Abdellatif Errami; Jordy Coffa; Hugo Bock; Maria Luiza Saraiva-Pereira; Patricia Ashton-Prolla; João Carlos Prolla
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

10.  Evaluating Lynch syndrome in very early onset colorectal cancer probands without apparent polyposis.

Authors:  Kory W Jasperson; Thuy M Vu; Angela L Schwab; Deborah W Neklason; Miguel A Rodriguez-Bigas; Randall W Burt; Jeffrey N Weitzel
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.